Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
about
Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinomaLong lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells.Afatinib for the treatment of advanced non-small-cell lung cancer.Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.Current biologics for treatment of biliary tract cancers.Intravital biobank and personalized cancer therapy: the correlation with omics.
P2860
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Phase 2 trial of afatinib, an ...... creened for target activation.
@en
Phase 2 trial of afatinib, an ...... creened for target activation.
@nl
type
label
Phase 2 trial of afatinib, an ...... creened for target activation.
@en
Phase 2 trial of afatinib, an ...... creened for target activation.
@nl
prefLabel
Phase 2 trial of afatinib, an ...... creened for target activation.
@en
Phase 2 trial of afatinib, an ...... creened for target activation.
@nl
P2093
P2860
P50
P356
P1433
P1476
Phase 2 trial of afatinib, an ...... screened for target activation
@en
P2093
A John Iafrate
Carlos R Becerra
Eunice L Kwak
Florence Le Maulf
Geoffrey I Shapiro
Maximilian T Lobmeyer
Meghan Robohn
Seth M Cohen
Vikram K Chand
P2860
P304
P356
10.1002/CNCR.28120
P407
P577
2013-06-14T00:00:00Z